As a manufacturer and innovator, we Bioperfectus are always on the way to go beyond testing.

We today are pleased to announce that our SARS-CoV-2 antigen rapid test kit has been upgraded to meet higher market requirements:

• Clinically approved sensitivity: 97.1%
• Clinically approved specificity: 99.2%
• Multiple packaging: 1T/2T/5T/10T/15T/20T/25T/50T
• No drop in sensitivity in face of VOC1 Kent, UK, B1.1.7 and VOC2 South Africa, B.1.351
• Able to detect asymptomatic cases
• Optional positive control for quality assurance

For more information about our product, please send an inquiry email to info@bioperfectus.com, media cooperation & news release: marketing_global@bioperfectus.com.